Osteoporosis

Latest

Vitamin D Supplementation Has No Effect on Musculoskeletal Health

Vitamin D Supplementation Has No Effect on Musculoskeletal Health

There is little justification for the use of vitamin D supplements to maintain or improve musculoskeletal health.

Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis

Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis

Rates of incident clinical vertebral fracture, incident nonvertebral fracture, hip fracture, and clinical fractures decreased 6 months after initiation of teriparatide.

Genetic Screening May Predict Osteoporosis, Fracture Risk

Genetic Screening May Predict Osteoporosis, Fracture Risk

Genetic testing may identify individuals with an increased risk for osteoporosis and bone fracture.

Decreased Osteoporosis Treatment Initiation Observed After Hip Fracture

Decreased Osteoporosis Treatment Initiation Observed After Hip Fracture

Researchers observed a reduction in subsequent nonvertebral fracture rates in patients who initiated osteoporosis treatment.

Bone Mineral Density Loss Eventually Stabilizes in Men With Type 1 Diabetes

Bone Mineral Density Loss Eventually Stabilizes in Men With Type 1 Diabetes

Investigators determined that reductions in bone mineral density in men with type 1 diabetes occur early in the course of the disease.

Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA

Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA

Researchers observed no change in bone mineral density in patients with early and active rheumatoid arthritis who were treated with prednisone or prednisolone vs placebo.

Effect of Mediterranean Diet Plus Vitamin D3 on Bone Density in Osteoporosis

Effect of Mediterranean Diet Plus Vitamin D3 on Bone Density in Osteoporosis

Investigators examined the effect of consuming a Mediterranean-style diet for 1 year on inflammatory response and bone health in the elderly.

New Romosozumab BLA Includes Data from Additional Osteoporosis Trials

New Romosozumab BLA Includes Data from Additional Osteoporosis Trials

Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.

Romosozumab: Effective in Men With Osteoporosis

Romosozumab: Effective in Men With Osteoporosis

Romosozumab increased spine and hip bone mineral density after 12 months of treatment.

USPSTF Favors Osteoporosis Screening to Prevent Fracture

USPSTF Favors Osteoporosis Screening to Prevent Fracture

Screening with bone measurement is recommended for women. Younger women are at more risk.

Sign Up for Free e-Newsletters



CME Focus